Following up on an eventful 2016, this year brings plenty of value-creating events for marijuana stocks. Here’s what to look for with Insys Therapeutics (NASDAQ: INSY), GW Pharmaceuticals (NASDAQ: GWPH) and Corbus Pharmaceuticals Holdings (NASDAQ: CRBP). Continue Reading Below Image source: Getty Images. Schedule this Last July, Insys Therapeutics gained approval from the Food and […]

by

‘+ ‘ ‘+__tnt.truncateStr(oAsset.title,85,’…’)+’ ‘+ ‘ ‘+__tnt.truncateStr(oAsset.summary,iTextTrun,’…’)+’ ‘+ ‘ … read more at: http://host.madison.com/business/investment/markets-and-stocks/gw-pharmaceuticals-biggest-win-in/article_75adaf4c-55a7-537e-855f-d78c7b0c9cbd.html

by

When should prosecutors act like people, instead of like prosecutors? It’s a harder question to answer than you might think. The Washington Post reported this week on the murder of 21-year-old Grant Dosunmu, who was shot to death Sunday night while sitting in his car in one of the toniest neighborhoods in DC. A graduate […]

by

When should prosecutors act like people, instead of like prosecutors? It’s a harder question to answer than you might think. The Washington Post reported this week on the murder of 21-year-old Grant Dosunmu, who was shot to death Sunday night while sitting in his car in one of the toniest neighborhoods in DC. A graduate […]

by

Without a doubt, the biggest win for GW Pharmacueticals (NASDAQ:GWPH) in 2016 came from the clinical trial results for its marijuana-derived cannabidiol (CBD) drug candidate Epidiolex. GW Pharmaceuitcals has a drug on the market, Sativex, but with the company only recording revenue of $13.3 million during the 2016 fiscal year that concluded at the end […]

by

Repeated clinical success drove shares of GW Pharmaceuticals (NASDAQ: GWPH) about 60% higher in 2016, and an impressive 190% higher than low points in March. If you missed the boat last year, you’ll be happy to know there are at least three reasons this top marijuana stock could continue rising in the new year and […]

by

Kalytera Therapeutics Inc has entered into a binding letter of intent (LOI) to acquire Talent Biotechs Ltd, an Israeli-based developer of proprietary cannabidiol (CBD) therapeutics. Currently, Talent is advancing a phase 2 clinical program examining the use of CBD to prevent and treat Graft versus Host Disease (GvHD), according to a press release. GvHD is […]

by

Kalytera enters into binding letter of intent to acquire Talent Biotechs and its Phase 2 clinical-stage Graft versus Host Disease program. Kalytera Therapeutics, Inc. has entered into a binding letter of intent (LOI) to acquire all of the issued and outstanding securities of Talent Biotechs Ltd., a privately held, Israeli-based developer of proprietary cannabidiol (CBD) […]

by

Kalytera enters into binding letter of intent to acquire Talent Biotechs and its Phase 2 clinical-stage Graft versus Host Disease program. Kalytera Therapeutics, Inc. has entered into a binding letter of intent (LOI) to acquire all of the issued and outstanding securities of Talent Biotechs Ltd., a privately held, Israeli-based developer of proprietary cannabidiol (CBD) […]

by

Without a doubt, the biggest win for GW Pharmacueticals (NASDAQ:GWPH) in 2016 came from the clinical trial results for its marijuana-derived cannabidiol (CBD) drug candidate Epidiolex. GW Pharmaceuitcals has a drug on the market, Sativex, but with the company only recording revenue of $13.3 million during the 2016 fiscal year that concluded at the end […]

by

A controlled-realease hemp CBD (cannabidiol) chewing gum will be the subject of a new human clinical trial investigating the gum’s effects on alleviating symptoms of irritable bowel syndrome (IBS). Axim Biotechnologies (New York) announced this week that its CanChew Plus CBD gum has received approval from the Medical Ethical Committee of Wageningen University (The Netherlands) […]

by

DEVON, Pa., Jan. 19, 2017 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced the pricing of an underwritten public offering of 2.8 million shares of its common stock at a price of $18.00 per share, with expected gross proceeds […]

by